Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers

Article Pharmacology & Pharmacy

The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers

Qiao Zhang et al.

Summary: The study found that pretreatment with rifampicin significantly reduced the systemic exposure to fuzuloparib. A single administration of fuzuloparib after multiple oral doses of rifampicin was well-tolerated, without severe adverse events. The exposure of fuzuloparib was dramatically decreased when pretreated with rifampicin, indicating that strong CYP3A4 inducers should be avoided during fuzuloparib treatment.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects

Yicong Bian et al.

Summary: This study investigated the pharmacokinetics of the novel anesthetic HSK3486 in healthy subjects, demonstrating its rapid onset of action and favorable safety profile.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

A phase I study of fluzoparib tablet formulation, an oral PARP inhibitor: effect of food on the pharmacokinetics and metabolism after oral dosing in healthy Chinese volunteers

Min Wu et al.

Summary: The study found that food decreased the absorption rate and peak exposure time of fluzoparib, but did not significantly impact the AUC value. Most treatment-emergent adverse events were grade I or II.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy